PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today announced confirmation from three independent laboratories of NEUGENE(R) antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1.